The variability of individual tolerance to methotrexate in cancer patients
H H Hansen, O S Selawry, J F Holland, C B McCall, H H Hansen, O S Selawry, J F Holland, C B McCall
Abstract
Individual tolerance to single or widely spaced doses of methotrexate was explored in 49 patients with advanced cancer with normal serum creatinine and/or blood urea nitrogen. Methotrexate was given as an intravenous infusion over 1 hour at initial doses of 80-120 mg./m(2) body surface area. The doses were increased by 50% increments every 2 weeks until moderate toxicity occurred, arbitrarily defined as leukopenia <5000/mm.(3), and/or thrombocytopenia <100,000/mm.(3), and/or the appearance of oral mucous or intestinal toxicity.The individual dose required to produce initial evidence of toxicity varied by a factor of 18 between 50 and 900 mg./m(2). Starting doses above 80 mg./m(2) were potentially hazardous. Dose limiting toxicity consisted of leukopenia with or without stomatitis in 81% of the patients, and stomatitis without leukopenia, in 19%. Thrombocytopenia was seen in 19% of the patients, but was never a dose limiting factor alone. Leukopenia always preceded thrombocytopenia. The nadir for haematologic toxicity varied considerably between day 5-15 and 9-14 for leukocytes and platelets, respectively, while oral ulcerations, when they occurred, consistently began between days 3-6 after drug administration. Other toxic manifestations included dermatologic changes in 8 patients, hepatic dysfunction in 7, conjunctivitis in 7, nausea and vomiting in 6, alopecia in 4, and diarrhea in 3 patients.The only factor which predicted toxicity was the patient's age. Drug tolerance was independent of previous chemotherapy or radiotherapy, weight loss, serum albumin or pretreatment serum folic acid levels.
References
- Clin Pharmacol Ther. 1969 Nov-Dec;10(6):849-57
- Science. 1969 Nov 14;166(3907):887-8
- Nature. 1962 Jan 13;193:140-2
- Cancer Res. 1963 Sep;23:1286-306
- Cancer Res. 1968 Jun;28(6):1088-94
- Presse Med. 1969 Mar 1;77(11):385-8
- J Natl Cancer Inst. 1956 Aug;17(2):203-12
- J Pharmacol Exp Ther. 1962 Aug;137:167-72
- Blood. 1962 Nov;20:609-16
- JAMA. 1968 May 13;204(7):561-4
- J Clin Invest. 1963 Apr;42(4):466-75
- Cancer Res. 1970 Jun;30(6):1782-8
- Cancer Res. 1967 Mar;27(3):490-7
- Arch Surg. 1970 Feb;100(2):173-7
- Cancer. 1966 Apr;19(4):600-6
- Cancer. 1960 Mar-Apr;13:222-8
- Cancer Res. 1969 Dec;29(12):2384-9
- Cancer. 1960 Mar-Apr;13:245-9
- Cancer Res. 1965 Feb;25:221-4
- Cancer Res. 1962 Jul;22:706-12
- Cancer Res. 1970 Aug;30(8):2132-8
Source: PubMed